Finance / RCI (RENAL CARE GROUP INC)

Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results Press Release Source: Ardea Biosciences, Inc. On 8:00 am EST, Friday November 6, 2009 Companies:Ardea Biosciences, Inc. SAN DIEGO, Nov. 6 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA - News), a biotechnology company focused on the development of small-molecule ...

Keryx Biopharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference Date : 10/29/2009 @ 8:30AM Source : PR Newswire Stock : (KERX) http://ih.advfn.com/p.php?pid=nmona&cb=1256843972& article=40114151&symbol=N^KERX Presentation Scheduled for Wednesday, November 4th at 4:30PM ET NEW YORK, Oct 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today ...

CS: Cytokinetics Inc. (CYTK) OUTPERFORM [V] M. Aberman CP: US$ 4.27 TP: US$ 8 CAP: US$ 259.6m Delay in Omecamtiv Disapponiting but Offset by Advancement of CK-357, Raising Estimates and Target Price to $8 (from $7) • Action/Event: Cytokinetics reported GAAP EPS of ($0.14) on revenues of $ 5.5 M. The company also announced that Amgen will pursue additional PK work before moving omecamtiv ...

Cytokinetics, Incorporated Reports Third Quarter 2009 Financial Results Quarterly Highlights Include Company's Research and Development Day Elaborating on Expansion of Development Pipeline; Company Provides Update on Next Steps in Development of Omecamtiv Mecarbil Press Release Source: Cytokinetics, Inc. On 4:00 pm EDT, Wednesday October 28, 2009 Companies:Cytokinetics Inc. SOUTH SAN ...

Antigenics Reports Third Quarter 2009 Financial Results Conference Call Scheduled for Today at 11:00 a.m. Eastern Time Press Release Source: Antigenics Inc. On 7:00 am EDT, Thursday October 29, 2009 Companies:Antigenics Inc. LEXINGTON, Mass.--(BUSINESS WIRE)--Antigenics Inc. (NASDAQ: AGEN - News) reported today its results for the quarter ended September 30, 2009. The company incurred a net loss ...

Antigenics Reports Third Quarter 2009 Financial Results 43 minutes ago - Businesswire Related Companies Symbol Last %Chg AGEN 1.07 0.00% As of 4:00 PM ET 10/28/09 Antigenics Inc. (NASDAQ: AGEN ) reported today its results for the quarter ended September 30, 2009. The company incurred a net loss attributable to common stockholders ...

Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphos Date : 10/26/2009 @ 8:30AM Source : PR Newswire Stock : (KERX) http://ih.advfn.com/p.php?pid=nmona&cb=1256569334& article=40052709&symbol=N^KERX Phase 2 data on Zerenex as a treatment for hyperphosphatemia for dialysis patients requiring high doses of phosphate binders ...

Still not whet you are looking for; but still a good read with some of the stuff you are looking for such as projections on PPS and EPS. Couldn't get the link to work so I copied and pasted everything. Daegen View profile More options Oct 19, 2:11 am From: Daegen Date: Sun, 18 Oct 2009 23:11:25 -0700 (PDT) Local: Mon, Oct 19 2009 2:11 am Subject: The rising of MedaSorb. Guys, have a read on ...

RNN- New Animal Study Featured in the Journal of Cellular Biochemistry Supports Rexahn’s Archexin™ as Potent Inhibitor of Huma... Date : 10/22/2009 @ 8:00AM Source : Business Wire Stock : Rexahn Pharmaceuticals, Inc. (RNN) Quote : 0.69 0.0 (0.00%) @ 8:43AM New Animal Study Featured in the Journal of Cellular Biochemistry Supports Rexahn’s Archexin™ as Potent Inhibitor of Huma... Rexahn ...

New Animal Study Featured in the Journal of Cellular Biochemistry Supports Rexahn’s Archexin™ as Potent Inhibitor of Huma... Date : 10/22/2009 @ 8:00AM Source : Business Wire Stock : Rexahn Pharmaceuticals, Inc. (RNN) Quote : 0.69 0.0 (0.00%) @ 8:43AM New Animal Study Featured in the Journal of Cellular Biochemistry Supports Rexahn’s Archexin™ as Potent Inhibitor of Huma... Rexahn Pharmaceuticals...